{
    "body": "What are the side effects during statins administration in patients with atherosclerosis?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25678839", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24840269", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21796961", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21267417", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12891851", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27878791", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17042673", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24788803", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25644328", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19039148", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26490078", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26575138", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24601937", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25936326", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18585718", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22913216", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23299641", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21972203"
    ], 
    "ideal_answer": [
        "The side effects during statins administration in patients with atherosclerosis are:\n1) Myopathy\n2) Transaminase elevations\n3) Diabetes mellitus \n4) Renal and neurologic adverse effects."
    ], 
    "exact_answer": [
        [
            "Myopathy"
        ], 
        [
            "Transaminase elevations"
        ], 
        [
            "Diabetes mellitus"
        ], 
        [
            "Renal adverse effects"
        ], 
        [
            "Neurologic adverse effects"
        ]
    ], 
    "type": "list", 
    "id": "589c4c9078275d0c4a000040", 
    "snippets": [
        {
            "offsetInBeginSection": 1081, 
            "offsetInEndSection": 1224, 
            "text": "A history of side effects was reported by 40 (19.5%) of the patients, and mainly consisted of muscle complaints and gastrointestinal symptoms. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25644328", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 56, 
            "text": "Treatment Options for Statin-Associated Muscle Symptoms.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26575138", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 383, 
            "offsetInEndSection": 457, 
            "text": "Muscle symptoms are a clinically relevant side effect of statin treatment.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26575138", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 641, 
            "offsetInEndSection": 727, 
            "text": "At least 5% of patients taking statins have statin-associated muscle symptoms (SAMS). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26575138", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 237, 
            "text": "Muscle problems and other adverse symptoms associated with statin use are frequent reasons for non-adherence and discontinuation of statin therapy, which results in inadequate control of hyperlipidemia and increased cardiovascular risk. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26490078", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 632, 
            "offsetInEndSection": 838, 
            "text": "It was estimated that rosuvastatin-associated absolute hazards of muscle-, liver- and renal-related adverse effects are lower than the corresponding vascular benefits in moderate vascular risk individuals. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24788803", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1654, 
            "offsetInEndSection": 1856, 
            "text": "Rosuvastatin-induced proteinuria appears to be of tubular origin, not relating to kidney injury. Rosuvastatin increases the risk of new-onset diabetes by dose-dependently impairing insulin sensitivity. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24788803", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 469, 
            "offsetInEndSection": 736, 
            "text": "Statins are associated with myopathy, transaminase elevations, and an increased risk of incident diabetes mellitus among some patients; connections between statins and other processes, such as renal and neurologic function, have also been studied with mixed results. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24840269", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 371, 
            "offsetInEndSection": 696, 
            "text": "Muscle symptoms are a clinically relevant side effect of statin treatment.This review is based on pertinent publications retrieved by a selective literature search, and on the current recommendations of the European Atherosclerosis Society.At least 5% of patients taking statins have statin-associated muscle symptoms (SAMS).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26575138", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1018, 
            "offsetInEndSection": 1239, 
            "text": "Nevertheless, patients may develop side effects such as muscle pain and weakness years after starting statin therapy; however, the absolute number of patients affected by statin myopathy increases with treatment duration.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23299641", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1122, 
            "offsetInEndSection": 1311, 
            "text": "Better understanding of the molecular mechanisms involved in statin-induced myopathy may help identify patient groups susceptible to statins' side effects, thereby increasing their safety..", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18585718", 
            "endSection": "abstract"
        }
    ]
}